Dr. Marina Udier comments the Neoantigen vaccine report card issued by BioCentury
Please find the full report below:
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
BASEL, Switzerland – 15th November 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient has [...]
Nouscom’s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors
7th November 2022 – Initial data from Phase 1b trial evaluating NOUS-PEV in combination with pembrolizumab to be presented at SITC 2022 Nouscom, a clinical stage immuno-oncology company [...]
Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit
Our Co-Founder and CSO Dr. Elisa Scarselli will join as Expert Speaker at the virtual Neoantigen Based Therapies Summit from October 26 – 28, 2021. Find out more about the conference and [...]
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
BASEL, Switzerland – 9th September 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the [...]
Nouscom new Science Translational Medicine publication highlighted on Cancer Discovery #ResearchWatch
Nouscom new Science Translational Medicine publication is highlighted on Cancer Discovery #ResearchWatch, describing a novel mechanism of action driven by viral vector-based vaccine platform [...]
Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy
11th August 2022 – Research paper published in Science Translational Medicine by Nouscom and the Armenise-Harvard Laboratory of Immunoregulation at IIGM led by Luigia Pace describes how [...]
Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022
6th June 2022 – NOUS-209 in combination with pembrolizumab is safe, highly immunogenic, and associated with promising early and long-term clinical efficacy in 20 MSI-H GI patients Nouscom, [...]
Nouscom to Present Full Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022
BASEL, Switzerland – 27th May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced that full [...]
Nouscom Announces Promotion of Richard Davis to Chief Operating Officer
BASEL, Switzerland –23rd May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the promotion [...]
